Wall St futures point to higher start for equities Oct 8, 2009
Savient Pharmaceuticals (SVNT.O) fell 6 percent in after-hours trade on Wednesday following the company's announcement of an offering of four million shares of stock. U.S. asset manager BlackRock Inc (BLK.N) is in the running to help state regulators estimate risks in insurers' investments, the Wall Street Journal said, citing regulators and a National Association of Insurance Commissioners official. (Yahoo News -- Press Releases)
Opportunities in the Obesity Epidemic Sep 2, 2009
And on Aug. 2, the FDA delayed another treatment for the disease, Krystexxa from Savient Pharmaceuticals, which was ordered to submit new data on side effects and the manufacturing process. The problems of obesity go far beyond gout. (BusinessWeek)
S&P 500 Eclipses 1000 Amid Recovery Aug 4, 2009
Savient Pharmaceuticals (SVNT) plunged 20% after the drug maker warned last week its gout drug Krystexxa was rejected by regulators. The FDA cited deficiencies with the chemistry, manufacturing and controls section of the drugs application. (Fox News)
Gout treatment fails to win approval Aug 3, 2009
WASHINGTON - Savient Pharmaceuticals Inc., a money-losing biotechnology company whose only drug lost patent protection in 2006, has failed to win US approval to sell a new gout treatment because regulators need more information. The Food and Drug Administration issued a so-called complete-response letter, raising issues including the manufacturing process for the medicine, Krystexxa, and guidelines on evaluating its safety and efficacy, the company said. (Boston Globe)
Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM) Aug 3, 2009
EAST BRUNSWICK, N.J., Aug. 2 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: ) today announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) stating that the FDA can not at this time approve the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy ... "While our timeline for resubmission to the FDA is subject to a... (PR Newswire)
5 Stocks Bucking the Downtrend Jul 7, 2009
Savient Pharmaceuticals (Nasdaq: SVNT). . (MSNBC -- Business)
Split Decision for Stocks Jun 18, 2009
Savient Pharmaceuticals (SVNT) surged by more than 30% after an FDA panel recommended greenlighting its experimental gout drug for certain patients. The agency is expected to rule on the arthritis drug Krystexxa by August 1. (Fox News)
FDA Panel Backs Savient Pharmaceuticals' Gout Drug Jun 17, 2009
FDA panel says gout drug from Savient Pharmaceuticals should be approved, shares soar ... A panel of arthritis experts say a gout drug made by Savient Pharmaceuticals should be approved, despite some reports of heart problems in patients tested with the drug. (ABC News -- Wire)
New gout drug works, with risks, FDA says Jun 16, 2009
WASHINGTON - The Food and Drug Administration said Friday the Savient Pharmaceuticals drug Krystexxa appears to successfully treat gout, despite evidence of potentially deadly side effects. The FDA has been reviewing the company's drug application since December and has already delayed a decision on the drug once, leading some analysts to question whether it can win approval. (MSNBC -- Health)
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results May 7, 2009
EAST BRUNSWICK, N.J., May 6 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: ) today reported financial results for the three months ended March 31, 2009 ... ABOUT SAVIENT PHARMACEUTICALS, INC. ... Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. (PR Newswire)
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results Feb 26, 2009
EAST BRUNSWICK, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: ) today reported financial results for the three months and year ended December 31, 2008 ... ABOUT SAVIENT PHARMACEUTICALS, INC. ... Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs focusing in rheumatology and other niche markets. (PR Newswire)
Savient Provides Update on Pegloticase BLA Feb 13, 2009
EAST BRUNSWICK, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: ) today announced that the Company filed amendments to strengthen and clarify the data included in the previously submitted pegloticase Biologics License Application (BLA), which was granted priority review ... ABOUT SAVIENT PHARMACEUTICALS, INC. ... Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical... (PR Newswire)
Savient Announces Appointment of David Gionco as Chief Financial Officer Feb 13, 2009
EAST BRUNSWICK, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: ) today announced the appointment of David G. Gionco to the position of Vice President, Chief Financial Officer & Treasurer ... "We are pleased to announce David's appointment. As our current Vice President of Corporate Finance and Controller, David will be able to seamlessly step in as Chief Financial Officer. Since joining Savient in 2006, David has distinguished himself as a true leader in the... (PR Newswire)
